Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Medtronic
UBS
Merck
Federal Trade Commission
Healthtrust
Teva
US Army
McKinsey

Generated: May 23, 2018

DrugPatentWatch Database Preview

ZEMPLAR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Zemplar patents expire, and what generic alternatives are available?

Zemplar is a drug marketed by Abbvie and is included in two NDAs. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has seventeen patent family members in ten countries.

The generic ingredient in ZEMPLAR is paricalcitol. There are ten drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the paricalcitol profile page.
Drug patent expirations by year for ZEMPLAR
Pharmacology for ZEMPLAR
Ingredient-typeCholecalciferol
Drug ClassVitamin D3 Analog
Synonyms for ZEMPLAR
(1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
(1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
(1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol
(1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol
(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,1R,4S)-5-hydroxy-1,4,5-trimethyl-hex-2-enyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
(7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol
131918-61-1
19-Nor-1-alpha,25-dihydroxyvitamin D2
19-Nor-1,25-(OH)2D2
19-Nor-1,25-dihydroxyvitamin D2
19-Nor-1alpha,25-dihydroxyvitamin D2
19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-
19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E)
6702D36OG5
918P611
Ab 122358
Abbott brand of paricalcitol
ABT-358
AC1NQY0Z
ACT07192
AKOS005145562
AN-15155
BC680819
BCP9001050
BDBM233195
BIDD:GT0330
BPKAHTKRCLCHEA-UBFJEZKGSA-N
C08127
CAS-131918-61-1
CHEBI:7931
CHEMBL1200622
Compound 49510
Compound-49510
CS-0705
D00930
D0N1TP
DB00910
DSSTox_CID_28566
DSSTox_GSID_48640
DSSTox_RID_82838
DTXSID4048640
GTPL2791
HSDB 7360
HY-50919
LMST04030163
LS-172812
MolPort-006-167-660
NCGC00182706-01
OR009715
OR213437
Paracalcin
Paricalcitol
Paricalcitol (JAN/USAN/INN)
Paricalcitol (USAN/INN)
Paricalcitol [USAN:USP:INN]
Paricalcitol [USAN]
Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin
PubChem18825
SC-20905
SCHEMBL3655
Tox21_112987
UNII-6702D36OG5
W-5365
Zemplar (TN)
ZINC13911941

US Patents and Regulatory Information for ZEMPLAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-003 May 26, 2005 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-002 May 26, 2005 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-001 Apr 17, 1998 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for ZEMPLAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-002 Feb 1, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-001 May 26, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-003 May 26, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ZEMPLAR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 2008-11-28
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 2008-10-14
➤ Subscribe Capsules 4 mcg ➤ Subscribe 2008-08-25

or, see our see our flat-rate plans

Supplementary Protection Certificates for ZEMPLAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/003 United Kingdom ➤ Try a Free Trial PRODUCT NAME: PARICALCITOL; REGISTERED: ES SPAIN 64.974 20020809; UK PL 00037/0403 20030721
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Boehringer Ingelheim
Deloitte
Teva
Harvard Business School
Mallinckrodt
Baxter
US Department of Justice
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.